100 related articles for article (PubMed ID: 20482528)
81. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman A; Yellin M; Keler T
Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
[TBL] [Abstract][Full Text] [Related]
82. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
83. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
84. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
85. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
86. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
87. Altering immune tolerance therapeutically: the power of negative thinking.
Prud'homme GJ
J Leukoc Biol; 2004 Apr; 75(4):586-99. PubMed ID: 14657212
[TBL] [Abstract][Full Text] [Related]
88. Recent advances using anti-CTLA-4 for the treatment of melanoma.
Sarnaik AA; Weber JS
Cancer J; 2009; 15(3):169-73. PubMed ID: 19556898
[TBL] [Abstract][Full Text] [Related]
89. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors.
Agarwala SS; Ribas A
J Immunother; 2010; 33(6):557-69. PubMed ID: 20551840
[TBL] [Abstract][Full Text] [Related]
90. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
Robert C; Ghiringhelli F
Oncologist; 2009 Aug; 14(8):848-61. PubMed ID: 19648604
[TBL] [Abstract][Full Text] [Related]
91. Clinical deployment of antibodies for treatment of melanoma.
Curti BD; Urba WJ
Mol Immunol; 2015 Oct; 67(2 Pt A):18-27. PubMed ID: 25746916
[TBL] [Abstract][Full Text] [Related]
92. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
Page DB; Yuan J; Wolchok JD
Immunotherapy; 2010 May; 2(3):367-79. PubMed ID: 20635901
[TBL] [Abstract][Full Text] [Related]
93. Update on anti-CTLA-4 antibodies in clinical trials.
Langer LF; Clay TM; Morse MA
Expert Opin Biol Ther; 2007 Aug; 7(8):1245-56. PubMed ID: 17696822
[TBL] [Abstract][Full Text] [Related]
94. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.
Di Giacomo AM; Biagioli M; Maio M
Semin Oncol; 2010 Oct; 37(5):499-507. PubMed ID: 21074065
[TBL] [Abstract][Full Text] [Related]
95. Checkpoint blockade in cancer immunotherapy.
Korman AJ; Peggs KS; Allison JP
Adv Immunol; 2006; 90():297-339. PubMed ID: 16730267
[TBL] [Abstract][Full Text] [Related]
96. Overcoming immunological tolerance to melanoma: Targeting CTLA-4.
Hodi FS
Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S16-23. PubMed ID: 20482528
[TBL] [Abstract][Full Text] [Related]
97. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
98. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
99. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
Wolchok JD; Saenger Y
Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
[TBL] [Abstract][Full Text] [Related]
100. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]